Cochlear Implant in India
Get Cochlear Implant at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Approximate cost range: $12,000 – $20,000
Cochlear Implant in UAE
Cochlear Implant at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Cochlear implant surgery is a life-changing auditory rehabilitation procedure that bypasses damaged hair cells in the cochlea to directly stimulate the auditory nerve, restoring functional hearing in patients with severe-to-profound sensorineural hearing loss. With overall device activation success rates exceeding 95% and speech recognition outcomes improving to 70–90% in optimal candidates, it represents the gold standard of hearing rehabilitation. GAF Healthcare connects international patients to JCI- and NABH-accredited cochlear implant centres in India and JCI- and DHA-licensed facilities in Dubai and Abu Dhabi, combining world-class surgical expertise with comprehensive medical tourism support at a fraction of Western costs.
Hospital Stay: 2–4 days • Total Stay in Country (Fit-to-Fly): 3–4 weeks (device activation and initial mapping must be completed before long-haul travel) • Success Rate: 95%+ device activation; 70–90% open-set speech recognition in optimal adult candidates
What Is It?
Sensorineural hearing loss (SNHL) affecting the cochlea accounts for over 90% of all profound deafness worldwide. The underlying pathology involves irreversible degeneration or congenital absence of the outer and inner hair cells of the organ of Corti, which are the mechanosensory transducers responsible for converting acoustic vibrations into electrochemical signals along the vestibulocochlear nerve (CN VIII). When hair cell populations fall below a functional threshold, conventional amplification devices such as hearing aids can no longer compensate, because there are insufficient biological transducers to amplify. At this stage, cochlear implantation offers the only evidence-based surgical solution.
A cochlear implant system comprises two primary components: an externally worn sound processor with a microphone and transmitter coil, and a surgically implanted receiver-stimulator connected to an intracochlear electrode array. The electrode array — typically 16 to 24 contacts in contemporary devices from manufacturers such as Cochlear (Nucleus), MED-EL (SYNCHRONY), and Advanced Bionics (HiRes Ultra) — is advanced along the scala tympani of the cochlea to span its tonotopic gradient. Electrical pulses delivered to discrete electrodes stimulate spiral ganglion neurons at frequency-specific locations, recreating a coded approximation of the acoustic signal that the brain learns to interpret as speech and environmental sound.
The global standard of care mandates a multidisciplinary evaluation before surgery, including pure-tone and speech audiometry, CT temporal bone and MRI internal auditory canal imaging, vestibular assessment, and psychological readiness counselling. Post-surgical auditory rehabilitation — structured auditory-verbal therapy (AVT) and speech-language pathology — is considered inseparable from surgical success and continues for 12–24 months post-activation. India and the UAE both host internationally benchmarked cochlear implant programmes staffed by surgeons trained at centres such as the House Ear Institute, Hannover Medical School, and Guy's Hospital London, ensuring outcomes comparable to North American and European standards.
Candidates
Ideal Surgical Candidates:
• Adults with bilateral severe-to-profound SNHL (pure-tone average >70 dB HL in the better ear) who derive limited benefit from optimally fitted hearing aids (word recognition scores <50% in the best-aided condition)
• Children aged 12 months and older (or younger in cases of meningitis-related ossification, where prompt intervention prevents cochlear fibrosis) with bilateral profound SNHL confirmed on auditory brainstem response (ABR) and auditory steady-state response (ASSR) testing
• Patients with single-sided deafness (SSD) or asymmetric hearing loss who experience significant handicap, including intractable tinnitus
• Pre-lingual and peri-lingual deaf individuals who demonstrate cortical auditory plasticity on functional assessments
• Post-lingual deaf adults regardless of duration of deafness, though shorter durations of auditory deprivation correlate with superior speech perception outcomes
Required Pre-Operative Diagnostics:
• High-resolution CT scan of the temporal bones (1 mm cuts, axial and coronal): to assess cochlear anatomy, detect ossification, evaluate round window niche, and plan electrode insertion depth and angle
• MRI of the internal auditory canals (T2 FIESTA/CISS sequences, 0.8 mm resolution): to confirm auditory nerve integrity, exclude retrocochlear pathology (acoustic neuroma), and detect endolymphatic hydrops
• Comprehensive audiological battery: pure-tone audiogram, tympanometry, acoustic reflexes, speech recognition threshold (SRT), and word recognition scores (WRS) with and without hearing aids
• Auditory Brainstem Response (ABR) and Auditory Steady-State Response (ASSR): mandatory in paediatric candidates who cannot provide reliable behavioural responses
• Vestibular function testing (video head impulse test, caloric testing): baseline documentation given surgical risk to the vestibular labyrinth
• Cardiac and anaesthetic pre-assessment (ECG, full blood count, coagulation profile, metabolic panel, chest X-ray): standard for any general anaesthesia case
• Psychological and speech-language evaluation: readiness assessment, expectations counselling, and baseline communication skills documentation
• Genetic testing (GJB2/Connexin 26 mutation panel): recommended in paediatric congenital SNHL to confirm aetiology and predict rehabilitative trajectory
Contraindications:
• Absent or severely hypoplastic cochlear nerve (Michel aplasia, complete cochlear aplasia) confirmed on MRI — absolute contraindication to standard cochlear implantation (auditory brainstem implant may be considered)
• Active suppurative otitis media or mastoiditis — requires resolution before implantation
• Complete cochlear ossification (labyrinthitis ossificans grade III) — may preclude full electrode insertion; modified surgical techniques (drill-out, split-electrode) can be considered
• Severe cognitive or neurological impairment limiting auditory learning and rehabilitation engagement
• Uncontrolled systemic coagulopathy or cardiovascular disease creating unacceptable anaesthetic risk
• Unrealistic patient or family expectations not resolved after comprehensive counselling
Procedure
Surgical Approaches:
1. Standard Cochleostomy Technique: The traditional approach involves a cortical mastoidectomy, posterior tympanotomy (facial recess approach), and creation of a separate cochleostomy anterior and inferior to the round window membrane. The electrode array is introduced through this drilled opening. This approach is widely practiced and offers reliable access across varied anatomy, including cases with a narrow facial recess.
2. Round Window Membrane (RWM) Insertion — The Preferred Atraumatic Technique: Contemporary evidence strongly supports insertion directly through the round window membrane without cochleostomy drilling. RWM insertion preserves intracochlear anatomy, minimises bone dust contamination of perilymph, reduces intracochlear trauma to residual hair cells, and significantly improves preservation of residual low-frequency hearing (acoustic hearing). This is now the standard of care at high-volume implant centres and is mandated in candidates for Electro-Acoustic Stimulation (EAS) or hybrid cochlear implants.
3. Electro-Acoustic Stimulation (EAS) / Hybrid Implant: Designed for candidates with significant residual low-frequency hearing but severe high-frequency SNHL. A short, flexible electrode array (e.g., MED-EL FLEX EAS, Cochlear Nucleus Hybrid L24) is inserted to a shallow depth (~20 mm), preserving apical hair cells. Combined with a hearing aid component in the same ear, EAS delivers electrical stimulation for high-frequency speech cues and acoustic amplification for low-frequency sounds — resulting in superior speech-in-noise performance compared to either modality alone.
4. Minimally Invasive Cochlear Implantation (MICI) — Robotic-Assisted Drilling (RobOtol / Healix): Emerging robotic cochlear implantation platforms guide a drill through the facial recess using pre-operative CT-planned trajectories with sub-millimetre accuracy, dramatically reducing surgical time and the risk of facial nerve injury. Robotic approaches are available at select quaternary centres in India (including AIIMS New Delhi and CMC Vellore) and are being introduced at advanced ENT centres in Dubai. This represents the frontier of minimally invasive otology.
5. Bilateral Simultaneous vs. Sequential Implantation: Bilateral cochlear implantation (both ears implanted) is the gold standard for paediatric patients, substantially improving sound localisation and speech perception in noise. Simultaneous bilateral surgery is performed in a single anaesthetic session, reducing cumulative risk. Sequential bilateral implantation is chosen when anaesthetic risk favours staged procedures. Both strategies are available at GAF Healthcare partner centres.
6. Auditory Brainstem Implant (ABI): In patients with bilateral absent cochlear nerves (neurofibromatosis type 2, cochlear nerve aplasia), an electrode array is surgically placed directly on the cochlear nucleus of the brainstem via a retrosigmoid craniotomy. Outcomes are more variable than cochlear implants, but ABI represents the only viable auditory rehabilitation option in cochlear nerve agenesis.
Implant Device Selection:
• Cochlear Nucleus Profile Plus (CI632): MRI-conditional at 3.0 Tesla without magnet removal; 22 electrodes; SmartSound iQ processing; Bluetooth LE streaming.
• MED-EL SYNCHRONY 2: Full MRI compatibility at 3.0 Tesla without removal; 12 electrode pairs spanning full cochlear length (31.5 mm); unique split electrode design for EAS.
• Advanced Bionics HiRes Ultra 3D: MRI-conditional at 3.0 Tesla; 16 electrode pairs; HiRes Optima signal processing; ClearVoice noise reduction.
• Device selection is guided by cochlear anatomy, residual hearing, MRI compatibility requirements, and patient lifestyle factors.
Cost of Cochlear Implant: India vs. UAE
Cochlear implant surgery involves both the surgical procedure cost and the cost of the implant device itself, which typically represents 50–60% of the total expenditure. India offers a compelling cost advantage — generally 50–65% lower than equivalent programmes in the UAE — driven by lower hospital operating costs, competitive surgical fees, and government-subsidised implant procurement schemes for eligible patients. The UAE, particularly Dubai and Abu Dhabi, provides a premium alternative with internationally trained surgeons, luxury hospital environments, and the advantage of easier logistics for patients travelling from the Middle East and Africa. Both destinations offer internationally accredited facilities and equivalent implant device technology.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $7,000 – $14,000 | ~58% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $18,000 – $32,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
Phase 1 — Remote Pre-Consultation (Weeks 1–2 before travel):
• Patient submits audiological reports, CT/MRI DICOM files, and medical history to GAF Healthcare's coordination team.
• GAF Healthcare forwards records to the assigned cochlear implant surgeon for a virtual consultation and candidacy determination.
• GAF Healthcare initiates e-Medical Visa application for India or advises on UAE entry requirements.
• Device brand and model are selected; import arrangements for the implant device are confirmed (critical in India where specific models may require advance procurement).
Phase 2 — Arrival and Pre-Operative Workup (Days 1–3 in country):
• GAF Healthcare provides airport transfer and check-in at partner hospital or affiliated recovery accommodation.
• In-person ENT and audiological assessment at the implant centre; formal surgery consent and anaesthesia consultation.
• Final high-resolution CT temporal bone and MRI IAC performed if not recently done (within 3 months).
• Paediatric cases include formal developmental and speech-language assessment.
• Blood panel, ECG, and anaesthetic fitness clearance obtained on Day 2.
Phase 3 — Surgery Day (Day 3 or 4):
• Cochlear implantation is performed under general anaesthesia and typically takes 2–3 hours per ear (3–5 hours for bilateral simultaneous).
• Intraoperative neural response telemetry (NRT/NRI) is performed to confirm electrode function and auditory nerve integrity.
• Intraoperative imaging (plain X-ray or cone-beam CT) may be obtained to verify full electrode insertion depth.
• Facial nerve monitoring is conducted throughout surgery using continuous electromyography (EMG) of facial musculature.
• Patient is observed overnight in the ward.
Phase 4 — Immediate Post-Operative Recovery (Days 4–6, in hospital):
• Wound inspection, removal of mastoid pressure dressing at 24 hours.
• Oral analgesia (typically NSAIDs and paracetamol); prophylactic broad-spectrum antibiotics continued for 5–7 days.
• Vestibular rehabilitation exercises commenced if postoperative dizziness is present (occurs in approximately 10–20% of cases, usually resolving within 1–2 weeks).
• Discharge on Day 2–3 post-surgery with wound care instructions and activity restrictions.
Phase 5 — Device Activation and Initial Mapping (Week 3–4 in country):
• At approximately 3–4 weeks post-surgery (when wound and tissue inflammation have stabilised), the external sound processor is fitted and the implant is activated by the audiologist — the 'switch-on' session.
• Initial programming ('mapping') establishes T-levels (threshold) and C-levels (comfort) for each electrode. Multiple mapping sessions over 3–7 days fine-tune the frequency-specific stimulation parameters.
• Auditory rehabilitation and listening therapy exercises begin immediately.
• This activation-and-mapping period is the primary reason international patients must remain in country for 3–4 weeks before it is safe to fly.
Phase 6 — Post-Departure Rehabilitation (Months 1–24):
• Remote mapping sessions via teleaudiology platforms (supported by GAF Healthcare partner audiologists in the patient's home country or via telemedicine) can supplement in-person follow-up.
• Formal auditory-verbal therapy (AVT) sessions recommended 2–3 times per week for 12–24 months.
• Hearing outcomes typically follow a trajectory: basic sound awareness at activation; sentence recognition at 3–6 months; conversational speech comprehension at 6–12 months; continuous improvement to 24 months.
• Follow-up CT or plain X-ray at 6 months to confirm electrode stability.
• Annual ENT review, audiological assessment, and processor software upgrade.
Risks & Considerations
Cochlear implantation is a low-mortality but technically complex microsurgical procedure, and patients should receive comprehensive risk counselling as part of the pre-operative process. Facial nerve injury is the most feared surgical complication: the facial nerve travels in close proximity to the surgical field within the facial recess, and even with continuous intraoperative electromyographic monitoring, transient paresis occurs in approximately 0.5–1% of cases, with permanent weakness in less than 0.2% at high-volume centres. Meningitis is a rare but serious delayed complication, primarily associated with the Pneumococcal, Haemophilus influenzae, and meningococcal organisms; vaccination (Pneumovax, PCV13, Hib, MenACWY) is mandatory at least 2 weeks before implantation in all candidates and is a strict pre-operative protocol requirement at GAF Healthcare partner centres. Wound infection and device extrusion occur in approximately 1–3% of cases and may rarely necessitate device explantation. Tinnitus may temporarily worsen immediately post-surgery before improving with device use in most patients. Postoperative vertigo and disequilibrium related to intracochlear trauma or endolymph disturbance affects 10–20% of patients and typically resolves within 2–4 weeks; chronic vestibular dysfunction is uncommon. Total device failure (implant malfunction requiring re-implantation) occurs at a rate of approximately 0.5–2% over a device lifetime and is covered under manufacturer warranty in most cases. Partial electrode insertion in cases of cochlear ossification may reduce the number of functional electrode contacts and limit ultimate hearing outcomes. Patients who undergo MRI after implantation must confirm MRI compatibility of their specific device model and follow manufacturer-specified field strength and protocol restrictions to avoid magnet displacement or artefact. Finally, speech perception outcomes are inherently variable and depend on age at implantation, duration of auditory deprivation, cochlear nerve integrity, cognitive reserve, and the intensity of post-operative rehabilitation. Patients must have realistic expectations established prior to surgery, particularly regarding residual hearing loss, environmental sound quality differences compared to normal hearing, and the extended rehabilitation timeline.
Top Hospitals for Cochlear Implant
Top Doctors for Cochlear Implant
Internationally trained specialists in ENT. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Ashish Vashishth
MBBS, MS (Otorhinolaryngology), DNB (Otorhinolaryngology), Fellow — European Board of Otorhinolaryngology & Head and Neck Surgery, Fellowship — Neurotology, Lateral Cranial Base Surgery & Advanced Auditory Implants, Joint European Diploma — Endoscopic Endonasal Skull Base Surgery
ENT Specialist & Cochlear Implant Surgeon
Manipal Hospital Dwarka, New Delhi, India
16+ Yearsof experience
Dr. Ashish Vashishth is Head of Department and Consultant ENT, Head & Neck and Cranial Base Surgery at Manipal Hospital Dwarka, New Delhi, with over 16 years of specialised surgical experience. He holds postgraduate qualifications including MS and DNB in Otorhinolaryngology, and is a Fellow of the European Board of Otorhinolaryngology & Head and Neck Surgery. His advanced training encompasses fellowship in neurotology, lateral cranial base surgery, and… Read more
Dr. Sudhir Dubey
MBBS — Sir Rupkishan Das Gold Medal, MCh (Neurosurgery) — Silver Jubilee Award
Neurosurgeon
Medanta – The Medicity, Gurugram, India
27+ Yearsof experience
Dr. Sudhir Dubey is the Chairman of Neurosurgery at the Neurosciences Division of Medanta – The Medicity, Gurugram. With over 27 years of experience in neurosurgery, he has performed more than 10,000 neurosurgical operations including pituitary surgery, skull base tumour resection, and complex spine surgery. He is widely regarded as one of the finest neurosurgeons in India. Dr. Dubey graduated from King George's Medical College with the prestigious Sir… Read more
Dr. T. S. Kler
MBBS, MD (Medicine), DM (Cardiology), MRCP (UK), FRCP (UK), FACC (USA), D.Sc (Honoris Causa)
Interventional Cardiologist & Electrophysiologist
BLK-Max Super Speciality Hospital, New Delhi, India
37+ Yearsof experience
Dr. T. S. Kler is the Chairman and Head of Department at BLK-Max Heart & Vascular Institute and Chairman of Pan Max Electrophysiology, serving as a leading interventional cardiologist and electrophysiologist. With over 37 years of clinical excellence, he holds distinguished international credentials including FRCP (UK), FACC (USA), and an honorary D.Sc. from Punjab University, recognising his pioneering contributions to cardiology. Dr. Kler's clinical… Read more
Dr. Gopi Srikanth
MBBS, MD Internal Medicine, DM Gastroenterology and Hepatology, Fellowship in Pancreatology, Fellowship in Endoscopic Ultrasound
Gastroenterologist
Yashoda Hospitals, Hyderabad, India
10+ Yearsof experience
Dr. Gopi Srikanth is a Consultant Gastroenterologist and Hepatobiliary specialist at Yashoda Hospitals in Hyderabad, bringing over 10 years of clinical expertise in digestive and liver disease management. He holds a DM in Gastroenterology and Hepatology from AIIMS New Delhi and completed advanced fellowships in Pancreatology and Endoscopic Ultrasound from prestigious institutions including the World Endoscopy Organisation, which distinguish him as a… Read more
Dr. Guruprasad Shetty
MBBS, MS (General Surgery), DNB (General Surgery), FMAS, FIAGES, Fellowship in Surgical Gastroenterology and Minimally Invasive Surgery
Surgical Gastroenterologist & Hepatobiliary Surgeon
Apollo Hospitals, Mumbai, India
15+ Yearsof experience
Dr. Guruprasad Shetty is a Senior Consultant in Surgical Gastroenterology, Hepatopancreaticobiliary, and Transplant Surgery at Apollo Hospitals in Mumbai, bringing over 15 years of specialized surgical expertise. He holds exceptional credentials including MBBS, MS in General Surgery, DNB, FMAS (Fellowship in Minimal Access Surgery), and FIAGES, alongside a specialized fellowship in Surgical Gastroenterology and Minimally Invasive Surgery. His… Read more
Frequently Asked Questions — Cochlear Implant
The all-inclusive cost of cochlear implant surgery in India through GAF Healthcare partner centres ranges from approximately USD 7,000 to USD 14,000 per ear, covering the surgical procedure, the implant device (from brands such as Cochlear, MED-EL, or Advanced Bionics), hospital stay of 2–4 days, anaesthesia, intraoperative neural response telemetry, initial audiological mapping sessions, and standard medications. In the UAE — specifically at JCI-accredited and DHA-licensed centres in Dubai and Abu Dhabi — the equivalent procedure ranges from USD 18,000 to USD 32,000 per ear, reflecting higher facility and surgical fees as well as the premium infrastructure of UAE private hospitals. India therefore offers a cost saving of 50–65% relative to the UAE. Both destinations use identical internationally approved implant devices; the difference lies in hospital operating costs and surgical fee structures, not device quality or clinical standards. Bilateral simultaneous implantation (both ears in one anaesthetic session) is available at both destinations and approximately doubles the device cost while adding a smaller proportional increase to surgical fees.
International patients undergoing cochlear implant surgery should plan to remain in India or the UAE for a minimum of 3 to 4 weeks before it is safe to take a long-haul international flight. This extended stay is not primarily due to surgical recovery — the wound typically heals well within 2 weeks — but is essential because the cochlear implant device cannot be activated immediately after surgery. The external sound processor is switched on approximately 3–4 weeks post-operatively, once post-surgical oedema in the tissues surrounding the implant has resolved sufficiently to allow accurate electrophysiological programming. The initial 'mapping' of the implant — during which the audiologist calibrates threshold and comfort levels for each of the 16–24 electrode contacts — requires multiple in-person sessions over approximately 5–7 days. Leaving the country before device activation and at least the first two mapping sessions creates a significant gap in care and can compromise early auditory learning outcomes. GAF Healthcare coordinates the full 3–4 week stay, including post-discharge accommodation, daily transport to mapping appointments, and remote teleaudiology continuation planning for after the patient returns home.
Cochlear implantation is among the most successful sensory restoration surgeries in modern medicine. Device activation success — defined as the implant functioning correctly and producing auditory perception upon switch-on — exceeds 95% at high-volume centres. In terms of functional hearing and speech understanding, outcomes depend significantly on patient-specific factors. Post-lingual adult patients (those who lost hearing after developing spoken language) who undergo implantation within 5–10 years of profound hearing loss onset achieve open-set sentence recognition scores of 70–90% in quiet listening conditions by 12 months post-activation in the best-documented series. Children implanted before 18–24 months of age who receive intensive auditory-verbal therapy have been shown to develop spoken language skills indistinguishable from hearing peers in multiple longitudinal studies. Post-lingual adults with longer durations of auditory deprivation and pre-lingual deaf adults who were never exposed to auditory speech experience more modest outcomes, with speech understanding typically in the 30–60% range. Device longevity is also excellent: modern cochlear implants have a design lifespan exceeding 70–100 years, with implant survival rates above 98% at 10 years reported by Cochlear and MED-EL in post-market surveillance data. Device failure requiring explantation and re-implantation occurs in less than 0.5–2% of cases over a device lifetime. GAF Healthcare partner centres report outcomes consistent with or exceeding published international benchmarks, supported by structured post-operative auditory rehabilitation programmes.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides an integrated, end-to-end coordination service that extends well beyond the surgical episode, recognising that cochlear implant patients typically require 3–4 weeks in-country and often travel with family caregivers.
Visa and Entry Facilitation:
• India: GAF Healthcare prepares and submits the Indian e-Medical Visa application on behalf of the patient and one accompanying attendant. The e-Medical Visa permits a 60-day stay, extendable, and is typically approved within 3–5 business days. We provide the required hospital invitation letter, cost estimate documentation, and application guidance through the Indian government's online portal.
• UAE (Dubai / Abu Dhabi): Citizens of over 50 countries including the UK, EU, USA, Canada, Australia, and GCC nations receive visa-on-arrival or visa-free access to the UAE for up to 30–90 days. GAF Healthcare advises on visa requirements specific to the patient's nationality and coordinates visa-on-arrival or pre-approved visit visa arrangements where needed.
Airport and Ground Transfers:
• Private, fully accessible airport transfers are arranged for arrival and departure at all major partner city airports (Delhi, Mumbai, Chennai, Hyderabad, Dubai, Abu Dhabi).
• All vehicles are equipped for patients with hearing difficulties; drivers are briefed and carry written communication aids where appropriate.
Language and Communication Support:
• Dedicated medical interpreters are available in Arabic, Russian, French, Swahili, Dari/Pashto, and other languages upon request for all clinical consultations, surgical consent, and audiological appointments.
• Written translation of all clinical reports, audiograms, and discharge summaries into the patient's preferred language is included in the GAF Healthcare coordination package.
Accommodation:
• For patients who do not require continuous hospitalisation during the activation-and-mapping phase (Weeks 3–4), GAF Healthcare arranges accommodation at partner serviced apartments or hospital-affiliated guesthouses within 10 minutes of the implant centre.
• Attendant accommodation is arranged in twin rooms at the same facility, with hospital meal packages available.
• Paediatric patients may require extended accommodation; GAF Healthcare coordinates furnished apartment rentals for families requiring 4–6 week stays.
Post-Discharge and Teleaudiology Coordination:
• GAF Healthcare maintains relationships with audiological rehabilitation centres globally to facilitate continuation of mapping and AVT upon the patient's return home.
• Patients are provided with the manufacturer's device-specific teleaudiology app configuration and connected to remote programming services where available (Cochlear Remote Check, MED-EL AudioKey, Advanced Bionics mySound).
• All medical records, operative reports, intraoperative imaging, programming maps, and rehabilitation protocols are compiled into a digital patient dossier provided at discharge for handover to home-country audiologists and ENT physicians.